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OBJECTIVE: PREDICTIVE was a large, multi-national, obser-
vational study assessing the safety and efﬁcacy of insulin detemir
(IDet) in real life clinical practice. The aim of this health eco-
nomic study was to assess the cost-effectiveness of Idet and
Insulin aspart (IAsp) versus human soluble insulin (HSI) and
neutral protamine Hagadorn (NPH) in patients with type 1 dia-
betes, based on the Czech sub-cohort of the PREDICTIVE study.
METHODS: A published and validated computer simulation
model was used to project long-term economic and clinical out-
comes in a simulated cohort of type 1 diabetes patients treated
with either IDet and IAsp or HSI and NPH, in a Czech setting.
Probabilities of complications and HbA1c-dependent adjust-
ments were derived from the PREDICTIVE trial. Complication
and treatment costs were obtained from Novo Nordisk s.r.o. and
projected over patient lifetimes from a societal perspective in the
Czech Republic. Future costs and clinical beneﬁts were dis-
counted at 5% per annum. RESULTS: IDet + IAsp versus
HIS + NPH treatment was projected to improve life expectancy
by approximately 0.17 years (11.52  0.14 versus 11.35  0.13
years) and quality-adjusted life expectancy by 0.70 quality-
adjusted life years (QALYs) (6.97  0.09 versus 6.28  0.08
QALYs). Treatment and complication costs associated with
IDet + IAsp treatment were projected to be lower over patient
lifetimes than with HIS + NPH (Czech Crowns (Kè) 921,722 
38,714 versus Kè 1,145,728  38,599 per patient, difference Kè
-224,006). IDet and IAsp were associated with a delay to the
onset of any diabetes-related complication by a mean of 0.17
years (0.77 versus 0.60 years). CONCLUSION: A Czech sub-
analysis of data from the PREDICTIVE study has demonstrated
cost and clinical beneﬁts for patients with type 1 diabetes.
IDet + IAsp treatment was projected to be associated with
improvements in life expectancy, QALYs and was cost saving
compared to NHP + HSI in the Czech setting.
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OBJECTIVE: Czech guidelines recommend additional therapy
with sulfonylurea, insulin or thiazolidinediones (TZD) after met-
formin monotherapy failure in type 2 diabetes. However TZD in
Czech are perceived to represent a cost intensive treatment com-
pared to insulin. The aim of this study was to assess annual direct
medical costs/reimbursement in patients treated either with 1)
rosiglitazon + metformin, or 2) insulin (monotherapy or combi-
nation) from the health care perspective. Further we performed
a cost-effectiveness calculation related to HbA1c decrease.
METHODS: Total 199 patients with completed 12 months TZD
or insulin treatment, who failed metformin monotherapy, were
included into the analysis. Following data were recorded retro-
spectively: Medication, consultations related to diabetes, hospi-
talization (incl. ward type and lengths), devices for insulin
application, patient education, selfmonitoring costs, sick-leave
and HbA1c values at the beginning and end of the assessed
period. Costs were calculated in 2007 prices. RESULTS: Age in
both groups was comparable. Insulin patients had signiﬁcantly
higher entry and ﬁnal HbA1c values (8.3% vs. 7.3% and 6.5%
vs. 6.0% p < 0.05). Insulin treated had higher mean annual costs
compared to TZD (€867 vs. €643 p < 0.05); however costs per
1% HbA1c decrease were comparable between groups (€475 vs.
€469). Mean total costs for a subgroup of patients who achieved
HbA1c of 6.0% (indicating satisfactory compensation) at the
end of assessment were also signiﬁcantly higher in the insulin
group (802€ vs. €610 p < 0.05) despite similar entry and ﬁnal
HbA1c levels. Costs per 1% HbA1c decrease were comparable
also in this subgroup (€375 vs. €366). CONCLUSION: Insulin or
TZD added on after metformin monotherapy failure in type 2
diabetes resulted in comparable costs per 1% HbA1c decrease.
Outcomes were robust also for patients who achieved HbA1c
levels of 6.0%. Both treatment options result in similar cost-
effectiveness from an annual perspective.
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OBJECTIVE: To determine the strategy most cost-effective
between Quinagolide, Bromocriptine and Cabergoline in patients
with Hyperprolactinaemia respect to the tumour percentage
reduction. METHODS: A cost-effectiveness analyses was made,
the efﬁcacy measures were obtained from a meta-analysis of
clinical trials of patients with hyperprolactinaemia who were
treated with some of the alternatives of the study. A microcosting
was performed through a pickup data instrument that was vali-
dated previously, the information was validated with a Mexican
panel experts. The perspective was from Mexican Institute of
Social Security. The parameters obtained were introduced to the
model (decision tree) in order to obtain the total cost average by
a Monte Carlo microsimulation with 100,000 iterations until
was obtained a mistake less than 3%. The variables used in the
analyses were the proportion of percentage reduction in tumour
mass with respect to the baseline, with the information obtained
was performed a Cost-effectiveness analyses and probabilistic
sensitivity analyses. RESULTS: The higher cost of the treatment
was with Bromocriptine (USD$3687) and the cheaper alternative
was Quinagolide (USD$3347). Quinagolide was the most effec-
tive option (80%) compared with Bromocriptine. The cost per
unit decreased in the percentage of tumour is smaller with
Quinagolide (USD$4184 ), while Bromocriptine and Cabergoline
have a higher cost (USD$6145 and USD$5243 respectively). The
incremental analyses show that Quinagolide was dominant. Bro-
mocriptine and Cabergoline are more expensive and less effective
(dominated). The sensitivity analyses of probabilistic type
showed that the Health Net Beneﬁts, Monetary Net Beneﬁts and
the Acceptability curves were favourable for Quinagolide inde-
pendently the willingness to pay. CONCLUSION: Quinagolide is
the dominant option in patients with Hyperprolactinaemia.
Quinagolide gives more Health Net Beneﬁts and Monetary Net
Beneﬁts that Bromocriptine and Cabergoline independently the
willingness to pay.
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